Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection
How two new early cancer detection companies aim to stand out from the pack
How two new early cancer detection companies aim to stand out from the pack.
The debut of two more venture-backed companies developing early cancer detection tests suggests there is still appetite for new approaches, even as bigger players consolidate via M&A and prepare for commercial launch.
Delfi Diagnostics Inc. raised an OrbiMed-led $100 million series A round to develop a test based on fragmentation patterns in plasma cell-free DNA (cfDNA), while Earli Inc. raised $40 million in support of its “synthetic biopsy”